Information analysis Center of Biogerontology and Regenerative Medicine is based on Laboratory of Genetics of Aging and Longevity of the Moscow Institute of Physics and Technology. The Center has been constituted for aging research and development of innovative life-extension technologies. Our partners are MIPT, “Northern” Biopharmaceutical Cluster, FSCC PHOI n.a. Dmitry Rogachev and The The Biogerontology Research Foundation.

The Centre is aimed to analyze anti-aging technologies, to overview perspective research guidelines, to create databases of aging biomarkers and geroprotectors, to design educational programs for learning age-related processes and possible ways to control them. By organizing seminars and conferences The Centre will promote development of international collaboration in the areas of biogerontology.

21 june 2014
Taking cancer cells out of circulation and grafting them into...
Taking cancer cells out of circulation and grafting them into mice allows to recreate properties, sensitivity to treatment and prognosis of small cell lung cancer. CTCs isolated from the peripheral blood of patients with small-cell lung cancer can become a model of characteristics of a patient’s primary tumor when grafted into a mouse model, including its response or resistance to standard chemotherapy.
20 june 2014
Oxytocin, hormone involved in lactation, parturition and social bonding, also...
Oxytocin, hormone involved in lactation, parturition and social bonding, also enables old mice’ muscles to rejuvenate after being injected into circulation. It stimulates muscle regeneration in old mice by boosting cell proliferation.
19 june 2014
BioLineRx Receives Approval to Commence Phase 1 Trial for Novel...
BioLineRx, biotechnological company placed in Israel receives approval for Phase 1 trial of stem cell mobilization treatment using small peptide drug Bl-8040.
18 june 2014
Activin receptor fusion proteins can be used in treatment of...
Celgene and Acceleron presented interim data from two studies of candidates from the companies' joint development program in beta-thalassemia. at the 19th European Hematology Association (EHA) annual congress. Sotatercept and aCE-536 demonstrated good activity in patients with both transfusion dependent and non-transfusion dependent beta-thalassemia.
17 june 2014
Biotechnological company Mesoblast presented positive results of Phase 2 clynical...
Biotechnological company Mesoblast presented positive results of Phase 2 clynical trial accessed use of Mesoblast’s Mesenchymal Precursor Cells (MPCs) in type 2 diabetes patients at American Diabetes Association annual meeting
17 june 2014
Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX...
Isis Pharmaceuticals announced positive final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. Significant HbA1c level reduction was achieved without impact on liver function or weight gain.